A Phase 4 interventional study of Metaxalone m640 mg oral tablet and Metaxalone 800 mg oral tablet in Healthy Participants, sponsored by Primus Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Primus Pharmaceuticals · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.
The Screening-Baseline Visit will include vital signs and urine testing, and a discussion of medications and current medical history. Participants will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk.
Visit 2 approximately one to two (1 to 2) week(s) later will be the first dosing day (Arm 1) after eating the high fat meal. The testing from Baseline will be repeated four (4) hours after the medication dose is taken.
Visit 3 approximately one (1) week later will be the second dosing day (Arm 2) after eating the high fat meal. The testing from Baseline will be repeated four (4) hours after the medication dose is taken.
The End of Study safety visit will take place one (1) week after Visit 3 by phone with a discussion of any side effects from the drug, recent medications, and any illness or injury experienced since the previous visit. Participants will be given end of study and discharge instructions.
Primus Pharmaceuticals is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metaxalone (M640) 640 mg tablet, a single-dose at visit 2 of 4 visits.
Drug: Metaxalone m640 mg oral tablet
Metaxalone 800 mg tablet, a single-dose at Visit 3 of 4 visits.
Drug: Metaxalone 800 mg oral tablet
Metaxalone partially micronized 640 mg tablet
Also known as: m640
Metaxalone non-micronized 800 mg oral tablet
Also known as: Skelaxin
Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test).
Validated 4-Stage Balance Test after completion of an FDA standardized high-fat meal. Place one foot in front of the other, heel touching toes.
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Change from baseline of gait during a stopwatch timed, stand, and walk activity from a seated position along a 30 foot path
Timed Up and Go with Triaxial Accelerometry
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Change from baseline of correct number of steps taken on a fixed 4 inch wide, 9 feet long path
Tandem Walk Test
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Change from baseline of participants' subjective report of drowsiness on a 10-point scale
Karolinska Sleepiness Scale where 1 = extremely alert and 10 = extremely sleepy, can't keep awake
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Change from baseline of reaction to stimulus by computer generated visual prompts measured in milliseconds
Reaction Time Test (RTT)
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
Change from baseline of participants' reasoning ability to recognize differences in six (6) computer generated shapes for 30 minutes
Creyos Cognitive Test
Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)
The number of product related adverse events experienced by participants from Visit 2 through Visit 4
Adverse and Serious Adverse Events
Time frame: Visit 2 dosing (Day 1, Visit 3 dosing (Day 8), Visit 4 End of Study (Day 15)
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Sep 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metaxalone
Primus Pharmaceuticals